Active substance
Indapamide
- SFDA 4
- US FDA 10
- Health Canada 4
- US price lines 2
- NHS prices 2
- WHO EML 2
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| NATRILIX 1.5 MG S.R TAB | 1.5 mg | Prolonged-release film-coated tablet · Oral use | 30 Blister | SAR 27.60 | NCE · Prescription | SERVIER | Valid |
| NORMALIX SR 1.5 mg modified-release tablet | 1.5 mg | modified-release tablet · Oral use | 30 Blister | SAR 24.65 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| NATRILLIX 2.5 MG. TAB | 2.5 mg | Tablet · Oral use | 30 Blister | SAR 27.20 | NCE · Prescription | SERVIER | Withdrawn by MAH · Not Marketed |
| PAMEDIX 1.5 MG S.R TAB | 1.5 mg | Tablet · Oral use | 30 Blister | SAR 22.20 | Generic · Prescription | Pharma International Co. | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
HYPERTENSION; PULMONARY ARTERIAL HYPERTENSION; RENAL AND URETERIC STONES
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| INDAPAMIDE | 2.5MG; 1.25MG | tablet · oral | ANI PHARMS | Prescription | 27 Jul 1995 |
| INDAPAMIDE | 2.5MG; 1.25MG | tablet · oral | RISING | Prescription | 27 Mar 1996 |
| INDAPAMIDE | 1.25MG; 2.5MG | tablet · oral | ACTAVIS ELIZABETH | Prescription | 17 Jun 1996 |
| LOZOL | 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | SANOFI AVENTIS US | Discontinued | 6 Jul 1983 |
| INDAPAMIDE | 1.25MG; 2.5MG | tablet · oral | CHARTWELL RX | Discontinued | 23 May 1996 |
| INDAPAMIDE | 1.25MG; 2.5MG | tablet · oral | WATSON LABS | Discontinued | 26 Sep 1996 |
| INDAPAMIDE | 2.5MG; 1.25MG | tablet · oral | ANI PHARMS | Discontinued | 31 Oct 1996 |
| INDAPAMIDE | 1.25MG; 2.5MG | tablet · oral | AUROBINDO PHARMA USA | Discontinued | 23 Jul 1998 |
| INDAPAMIDE | 1.25MG; 2.5MG | tablet · oral | ANI PHARMS | Discontinued | 4 Dec 1998 |
| INDAPAMIDE | 1.25MG; 2.5MG | tablet · oral | TEVA | Discontinued |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-INDAPAMIDE 1.25 MG TABLETS | 02245246 | 1.25 MG | TABLET · ORAL | APOTEX INC |
| APO-INDAPAMIDE 2.5MG TABLETS | 02223678 | 2.5 MG | TABLET · ORAL | APOTEX INC |
| MYLAN-INDAPAMIDE | 02153483 | 2.5 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-INDAPAMIDE | 02240067 | 1.25 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | INDAPAMIDE 1.25 MG TABLET | $0.10867 | per EA | 23 Sep 2026 |
| US NADAC | INDAPAMIDE 2.5 MG TABLET | $0.10761 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Indapamide 1.5mg modified-release tablets | £1.40 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Indapamide 2.5mg tablets | £2.84 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 12.3. Antihypertensive medicines · core
Therapeutic equivalent to hydrochlorothiazide for Essential hypertension - 12.4. Medicines used in heart failure · core
Therapeutic equivalent to hydrochlorothiazide for Heart failure
Safety signals and safety-related labeling changes
- US FDA 2 Mar 2021 LOZOL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - EMA PRAC 3 Oct 2019 PRAC signal: Choroidal effusion
Action for MAH: update of the product information: No
Combinations containing Indapamide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.